Rapid Pharmaceuticals, AG
Rapid Pharmaceuticals, AG Patent applications | ||
Patent application number | Title | Published |
---|---|---|
20110245180 | Modified Peptide that reduces pain in peripheral neuropathy - Chemokine signaling is important in neuropathic pain, with microglial cells expressing CCR2 playing a well established key role. DAPTA, a gp120-derived CCR5 entry-inhibitor has been shown to inhibit CCR5-mediated monocyte migration and to attenuate neuroinflammation. We disclose here that as a stabilized analog of DAPTA, the short peptide All D TTNYT exhibits potent antagonism for both CCR2 (IC | 10-06-2011 |